Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Copalia opvejer risiciene ved behandling af essentiel hypertension hos patienter, hvis blodtryk ikke er under tilstrækkelig kontrol med amlodipin eller valsartan alene.
The Committee for Medicinal Products for Human Use (CHMP) decided that Copalia’ s benefits are greater than its risks for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.